FDA Approves Trastuzumab Biosimilar for HER2+ Breast Cancer

December 17, 2018 – The FDA has granted an approval to CT-P6 (trastuzumab-pkrb), a trastuzumab biosimilar, for the treatment of patients with HER2-overexpressing breast cancer, according to Celltrion and Teva Pharmaceutical Industries, the co-developers of the agent. CT-P6 is indicated for patients with adjuvant breast cancer of HER2 overexpressing node-positive or -negative breast cancer to be used as part of a treatment regimen comprised of doxorubicin … (leggi tutto)